# SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer

Source: https://onco.cc/trials/nct06859775/  
OnCo record `nct06859775` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Trastuzumab rezetecan, Bevacizumab, SHR-8068 in cervical cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.

## Summary

SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer is a phase 1/2 interventional study registered as NCT06859775 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 100 participants planned, started 2025-04-25 and due to reach its primary completion in 2026-10. Interventions recorded: SHR-A1811, Adebelimab injection, Bevacizumab injection, SHR-8068, Cisplatin injection. Conditions listed: Recurrent or Metastatic Cervical Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06859775
- Phase: 1/2
- Setting: Open-label, Multicenter Phase Ib/II Clinical Study of Injectable SHR-A1811 in Combination Regimens for the Treatment of Recurrent or Metastatic Cervical Cancer
- Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT06859775: https://clinicaltrials.gov/study/NCT06859775

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [SHR-8068](https://onco.cc/drugs/shr-8068/), [Trastuzumab rezetecan](https://onco.cc/drugs/trastuzumab-rezetecan/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06859775.json